(S (NP-SBJ (NP (NNS Lymphocytes)) (PP (IN from) (NP (NN CML) (NNS patients)))) (VP (VBP lack) (NP (NP (DT a) (ADJP (CD 47) (NN kDa)) (NN factor)) (VP (VBG having) (NP (NP (NN affinity)) (PP (IN for) (NP (DT a) (JJ genomic) (NN sterol) (JJ regulatory) (NN sequence))))))) (. .))
(S (NP-SBJ-9 (VBN Deranged) (JJ cellular) (NN cholesterol) (NN homeostasis)) (VP (VBZ has) (VP (VBN been) (ADVP (RB widely)) (VP (VBN recognized) (NP (-NONE- *-9)) (PP (IN in) (NP (NP (DT the) (NP-COOD (NP (NN initiation)) (CONJP (RB as) (RB well) (IN as)) (NP (NN progression)))) (PP (IN of) (NP (NP (JJ various) (NNS types)) (PP (IN of) (NP (NNS cancers))) (PP (VBG including) (NP (NP (JJ chronic) (JJ myeloid) (NN leukaemia)) (PRN (-LRB- -LRB-) (NP (NN CML)) (-RRB- -RRB-))))))))))) (. .))
(S (SBAR (IN Since) (S (NP-SBJ-10 (DT the) (JJ human) (JJ genomic) (NP (NP (NN sterol) (JJ regulatory) (NN element)) (PRN (-LRB- -LRB-) (NP (NN SRE)) (-RRB- -RRB-)))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (NP-SBJ (-NONE- *-10)) (VP (TO to) (VP (VB regulate) (NP (NP (JJ various) (JJ key) (NNS genes)) (VP (VBN involved) (NP (-NONE- *)) (PP (IN in) (NP (DT this) (NN phenomenon))))))))))))) (, ,) (NP-SBJ (DT the) (JJ present) (NN study)) (VP (VBD revealed) (NP-COOD (NP (NP (DT the) (NN existence)) (PP (IN of) (NP (NP (DT a) (JJ unique) (ADJP (CD 47) (NN kDa)) (NN protein) (NN factor)) (VP (VBG having) (NP (NP (NN affinity)) (PP (IN for) (NP (DT this) (JJ SRE) (NN sequence))))))) (PP (IN in) (NP (NP (NNS lymphocytes)) (PP (IN from) (NP (JJ normal) (NNS subjects)))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (PRP$ its) (NN absence)) (PP (IN in) (NP (NP (NNS lymphocytes)) (PP (IN from) (NP (JJ untreated) (NN CML) (NNS patients)))))))) (. .))
(S (ADVP (RB However)) (, ,) (NP-SBJ (DT this) (NN factor)) (VP (VBD appeared) (SBAR-TMP (WHADVP-11 (WRB when)) (S (NP-SBJ (DT these) (NN CML) (NNS patients)) (VP (VBD achieved) (NP (NP (JJ complete) (JJ haematological) (NN remission)) (PRN (-LRB- -LRB-) (NP (NN CHR)) (-RRB- -RRB-))) (PP (IN through) (NP (NN alpha-interferon) (NN therapy))) (ADVP (-NONE- *T*-11)))))) (. .))
(S (ADVP (RB Furthermore)) (, ,) (NP-SBJ-12 (DT an) (JJ inverse) (NN relationship)) (VP (VBD was) (ADVP (RB also)) (VP (VBN observed) (NP (-NONE- *-12)) (PP (IN between) (NP-COOD (NP (NP (DT the) (NN LDL) (NN receptor) (NN gene) (NN expression)) (PP (IN at) (NP (DT the) (JJ transcriptional) (NN level)))) (CC and) (NP (NP (DT the) (NN binding) (NN affinity)) (PP (IN of) (NP (DT this) (ADJP (CD 47) (NN kDa)) (NN protein) (NN factor))) (PP (TO to) (NP (DT the) (NN SRE) (NN sequence)))))))) (. .))
(S (PP (VBN Based) (PP (IN upon) (NP (DT these) (NNS results)))) (NP-SBJ (PRP we)) (VP (VBP propose) (SBAR (IN that) (S (NP-SBJ (DT this) (NN factor)) (VP (MD may) (VP (VB have) (NP (DT a) (NN role)) (PP (IN in) (NP (NP (NN pathophysiology)) (PP (IN of) (NP (JJ chronic) (JJ myeloid) (NN leukaemia)))))))))) (. .))
